GRI
$2.58
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candi...
Recent News
Sector Update: Health Care Stocks Climb Late Afternoon
Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index up 1.8% and the Hea
Sector Update: Health Care Stocks Higher Thursday Afternoon
Health care stocks rose Thursday afternoon, with the NYSE Health Care Index up 1.4% and the Health C
GRI Bio reports six-week interim safety outcomes from trial of GRI-0621 for IPF
The trial was recommended by the interim analysis committee to proceed as per the plan.